TABLE 1

Baseline characteristics of the examined probands and patients

ProbandSexHLA alleles
Autoantibodies
DRB1*DQB1*GADAIA-2AIAAICA
T1D-1F0401,08010301,0302+++
T1D-2MNDND++ND+
T1D-3F1101,150301,0602
T1D-4M0301,060201/−++ND
T1D-5F0401,060302/−NDNDNDND
T1D-6F0405,060302/−++ND+
T1D-7M0401,04010301,0302++++
T1D-8F0701,0801NDNDNDNDND
T1D-9M0401,1301NDNDNDNDND
T1D-10M0401,04020302,0302++
T1D-11MNDND+++
T1D-12M0404,10010302,0501++
T1D-13F0401,04010301,0302NDNDNDND
T1D-14F0801,16010302,0502NDNDNDND
T1D-15M0301,04010201,0302
T1D-16F0401,04010302,0302NDNDNDND
T1D-17F0301,04010201,0302++++
T1D-18M0301,04010201,0302++
T1D-19M0301,04010201,0302++
T1D-20M0401,04010302,0301++++
T1D-21F0301,04010201,0302+++
T1D-22M0301,03010201,0201++
T1D-23M0401,04010302,0302+++
T1D-24FNDND
T1D-25F0401,070102,0302++
T1D-26M0401,04020302,0302++
T1D-27MNDND+++
T1D-28M0401,04040302,0302++
T1D-29FNDND++
T1D-30MNDND++
T1D-31F0301,0401ND
T1D-32F0301,04010201,0302+
Pre–T1D-1M0401,15010302,0602+ND+
Pre–T1D-2M0301,16010201,0502+ND+
Pre–T1D-3M0402,13010302,0603++++
Pre–T1D-4M0401,04010302,0302++++
Pre–T1D-5F0301,1601ND+
CP-1M0404,10010302,0501
CP-2M0301,04010201,0302
CP-3M0401,04010301,0302NDNDNDND
CP-4F0301,04010501,0301NDNDNDND
CP-5F0401,16010302,0502
CP-6F0401,13010302,0603NDNDNDND
CP-7F0401,15010302,0602
CP-8F0301,130201,0603NDNDNDND
CP-9M0301,110201/−NDNDNDND
CP-10F0301,04010201,0302
CP-11F0301,04080201,0301NDNDNDND
CP-12F0408,07010302,0303
CP-13F0401,16010502,0302NDNDNDND
CP-14M1501,040302,0602
CP-15M0401,1001ND
CP-16F0401,15010301,0602NDNDNDND
CP-17F1501,040302,0602
CP-18F0301,07010201,0201
CP-19F0401,13010302,0603
CP-20F0301,04010201,0302
CP-21M0401,03010302,0201
T2D-1F1001,150501,0602
T2D-2F0801,13010402,0603+
T2D-3F0701,12010201,0603
T2D-4MNDND
  • Normal range of autoantibodies: anti-GAD65 autoantibody (GADA) <3.9 Karlsburg units (KU)/l, anti–IA-2 autoantibody (IA-2A) <1.85 KU/l, anti-insulin autoantibody (IAA) <281.48 μU/l, and anti-ICA <20 JDF units. ND, not determined.